Guernsey firms Carey Olsen and Ipes have assisted Endeavour Vision on the fundraising of Endeavour Medtech Growth LP, which closed at its hard cap of €250 million having been oversubscribed. This makes it the largest dedicated medtech fund in Europe and one of the largest pure medtech funds worldwide.
Advised by healthcare and technology investor Endeavour Vision Ltd, the specialist fund is targeting European and US companies in the medical device and digital health sectors with products that have gained regulatory approval and are already generating commercial traction. Endeavour Vision Ltd is an internationally-recognised investor in the healthcare and technology sectors. The team includes successful investment professionals and world-class industry veterans and has executed more than 65 investments within its areas of focus.
The Carey Olsen team was led by partner David Crosland and included senior associates Jan Johannsson and Gemma Campbell. Advocate Crosland said: "Fintech often grabs the headlines but medtech is a huge and growing market that is offering exciting opportunities for investors. We were very pleased to support Endeavour Vision on this highly successful fundraise."
The Ipes team was led by Andrew Whittaker and James Nicolle. Andrew Whittaker said: "Endeavour’s continued confidence in Guernsey as a jurisdiction for their fund for the third time is a positive step forward. Using the National Private Placement Regime (NPPR) worked well and made their fund set up a smooth process. Ipes will be providing Endeavour with Administration, FATCA and AIFMD reporting services."